## EMN: Eastman Chemical Company - XLB: Basic Materials

### Executive Summary

No thesis match: MRS_20 1.6% below STRENGTH zone (4.0-10.0%); PEG 3.81 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($59.67)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Reassessing Eastman Chemical (EMN) After a Recent Bounce: Is the Stock Undervalued?**
- Source: Simply Wall Street | 20251221T120810 | Somewhat-Bullish | Relevance: 100%
- Eastman Chemical (EMN) has seen a recent 6.77% bounce, but remains down 28.20% year-to-date and in negative territory over five years. Despite this, the stock appears undervalued with a narrative fair value of $72.76 compared to its recent closing price of $63.56, suggesting potential for a turnaround driven by cost reductions and strategic optimization. Investors should consider the risks, such as trade tensions and uptake of recycled materials, which could delay margin expansion.

**2. Eastman Chemical (NYSE:EMN) Downgraded by Wells Fargo & Company to "Hold"**
- Source: MarketBeat | 20251220T123754 | Somewhat-Bearish | Relevance: 100%
- Wells Fargo & Company has downgraded Eastman Chemical (NYSE:EMN) from a "strong-buy" to a "hold" rating. This adjustment comes after several other brokerages also updated their ratings and price targets for EMN. The company recently reported third-quarter earnings that missed analyst expectations, with diluted EPS of $1.14 against an expected $1.18.

**3. RBC Capital Keeps Their Buy Rating on Eastman Chemical (EMN)**
- Source: The Globe and Mail | 20251220T000805 | Bullish | Relevance: 100%
- RBC Capital maintained a Buy rating on Eastman Chemical (EMN) with a $74.00 price target, following an analysis by Arun Viswanathan. Citi also reiterated a Buy rating on the stock with a $72.00 price target. Eastman Chemical reported quarterly revenue of $2.29 billion and a net profit of $140 million for the quarter ending June 30.

**4. Reassessing Eastman Chemical (EMN) After a Recent Bounce: Is the Stock Undervalued?**
- Source: Simply Wall Street | 20251221T120857 | Somewhat-Bullish | Relevance: 99%
- Eastman Chemical (EMN) has seen a recent 6.77% bounce, though its year-to-date performance is still down 28.20%. Despite the stock lagging, cost reduction initiatives and strategic optimization could lead to improved margins and a potential fair value of $72.76, suggesting it might be undervalued. However, factors like trade tensions and slower adoption of recycled materials could impact this outlook.

**5. Goelzer Investment Management Inc. Has $1.29 Million Stake in Eastman Chemical Company $EMN**
- Source: MarketBeat | 20251222T113146 | Neutral | Relevance: 96%
- Goelzer Investment Management Inc. significantly reduced its stake in Eastman Chemical Company by 43.7% in Q3, selling 15,849 shares but retaining a position valued at approximately $1.29 million. Other institutional investors like Vanguard Group Inc. and Invesco Ltd. increased their stakes. Eastman Chemical missed Q3 earnings estimates, but the company recently increased its quarterly dividend to $0.84 and provided FY2025 EPS guidance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Wells Fargo | $70 | $70 | 0% |
| 2025-12-18 | Citigroup | $72 | $70 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Wells Fargo | down | Equal-Weight |
| 2025-12-18 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 11 ($0.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.6% (-2.2%)
- Blackrock Inc.: 7.0% (+0.9%)
- State Street Corpora: 5.0% (+24.3%)
- Capital Research Glo: 3.7% (-1.0%)
- Dimensional Fund Adv: 3.5% (+14.4%)

### Key Risks

1. Valuation risk: PEG 3.8x with declining EPS estimates leaves no margin for error.
2. Long-term trend broken: trading 11.9% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.81 signals overvaluation risk, limited margin of safety. Forward P/E 10.3x attractive for 13% earnings growth. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $7.3B |
| Beta | 1.25 |
| 52W Range | $56.11 - $103.82 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.81 |
| Forward P/E | 10.3 |
| Current P/E | 11.6 |
| YoY Growth | 13.4% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from 5.2% to 1.6% (-3.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.4pp (needs >4.0% for momentum thesis). MRS_5 (-2.1%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.88x), long-term trend not supportive. RSI neutral at 54. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.56% (CS: 63) | Neutral |
| RSI_14 | 53.6 | Neutral |
| MACD Histogram | 0.11 | Bullish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.032x | Above |
| vs SMA200 | 0.881x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $63.25
- **Stop Loss:** $59.67 (5.7% risk)
- **Target:** $66.83 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 251
- **Position Value:** $15,875.75
- **Portfolio %:** 15.88%
- **Risk Dollars:** $900.00
- **Risk Per Trade:** 0.90%
- **Modifiers:** L1 120% | L2 75% | Combined 0.90x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-01-29 (Est: $0.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.14 | -2.2% |
| 2025Q2 | $1.75 | $1.60 | -8.7% |
| 2025Q1 | $1.89 | $1.91 | +1.2% |
| 2024Q4 | $1.57 | $1.87 | +18.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*